12:00 AM
 | 
Apr 25, 2011
 |  BC Week In Review  |  Company News  |  Deals

Arca biopharma, University of Cincinnati deal

Arca received exclusive, worldwide rights to a portfolio of U.S. and international patents from the university covering genetic polymorphisms of adrenergic cardiac receptors. The biotech believes the patents provide the necessary IP to develop a companion diagnostic for its heart failure candidate Gencaro bucindolol. Arca is currently developing the...

Read the full 232 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >